AbbVie talks next steps as first Humira competitor makes it to market

In AbbVie’s first earnings call since Humira’s first biosimilar came to market earlier this year, CEO Rick Gonzalez touted just over $58 billion in revenue for the Big Pharma in 2022 — and laid out guidance for how the company will fare over the next two years, despite the loss of its Humira monopoly.